SUNDAY, SEPTEMBER 25, 2016

Genetic analysis of dengue leads to synthetic vaccine

Synthetic vaccine developer Replikins, Ltd., announced on Tuesday that a new analysis of the gene structures in the dengue virus paved the way to a vaccine candidate.

The study examined data from Pubmed on all of its strains of dengue fever. The analysis revealed that the strains conserved and shared specific replikin structures dating back to 1944.

The discovery of the sharing of gene structures allowed Replikins to formulate its Synthetic Dengue Blocker-Vaccine candidate, similar to what it did for the H5N1 and Taura Syndrome Shrimp vaccines. Both of those vaccines have been effective.

The dengue vaccine candidate can be synthesized in five days and is available to governments and other institutions for testing and use according to the country's regulatory bodies.

Replikins are a group of peptides first identified by the propriety company that has trademarked the name Replikin Count. The increase of replikins in virus and other proteins is associated with rapid replication, which allows for the prediction of the infectivity and lethality of virus strains.

There is currently no licensed vaccine for dengue fever, which is a mosquito-borne illness that infects approximately 390 million people a year. The World Health Organization estimates that approximately half of the world's population is at risk of catching dengue.